Belgian Antithrombin Deficiency Registry

Antithrombin III Deficiency Clinical Trial

Official title:

Antithrombin Registry - Investigation of Phenotype-genotype Correlations in Patients With Inherited Antithrombin Deficiency

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05891899
• Other study ID #: UZB-ATRegistry
• Status: Not yet recruiting
• Start date: May 2024
• Est. completion date: December 2060

Study information

• Verified date: November 2023
• Source: Universitair Ziekenhuis Brussel
• Contact: Christelle Orlando, PhD
• Phone: 0032 4763528
• Email: christelle.orlando[@]uzbrussel.be
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Inherited antithrombin deficiency is a rare autosomal dominant disorder that predisposes to the development of venous thromboembolism, even at young age.

Inherited AT deficiency is considered the most severe form of inherited thrombophilia, increasing up to 40 times the risk of venous thrombosis.

Our center has been performing research on antithrombin deficiency for several years. Therefore, it was decided to initiate a registry for patients with inherited antithrombin deficiency with the goal to gain more insight into what drives the development of a thrombotic event in patients with AT deficiency, both at the environmental level (lifestyle, management of risk situations, presence of additional thrombotic risk factors…) and at the genetic level.

Description:

Background:

Antithrombin (AT) is the most important physiological inhibitor of blood coagulation, targeting predominantly factor X and thrombin (Factor II). It is a serine protease inhibitor encoded by the SERPINC1 gene and is synthesized in the liver. Inherited antithrombin deficiency is a rare autosomal dominant disorder that predisposes to the development of venous thromboembolism (VTE), even at young age. We can distinguish two types of AT deficiency: quantitative (type I) and qualitative (type II) deficiencies. According to which function of the protein is affected, type II deficiencies are subdivided into Heparin Binding Site (HBS), Reactive Site (RS) or Pleiotropic Effect (multiple functions or conformational consequences) deficiencies.

Inherited AT deficiency is considered the most severe form of inherited thrombophilia, increasing up to 40 times the risk of venous thrombosis. Antithrombin deficiency is a rare monogenic autosomal dominant disorder although the exact prevalence of AT deficiency remains largely unknown, probably because of the wide clinical heterogeneity. More than 400 different genetic variants in SERPINC1 have been identified. Diagnosis of AT deficiency is done by functional assays that are based on the inhibition of target proteases (Factor Xa or Factor IIa) in the presence of heparin. While biochemical, structural, and molecular information about AT is ample, there is a limited knowledge about the natural history of this disorder. The risk of venous thrombosis in carriers of AT deficiency is well documented but there are many important issues concerning the natural history of AT deficiency that must be unraveled: First, there is a remarkable heterogeneous presentation of AT deficiency. Type I deficiency has been associated with poorer prognosis than type II, but no systematic genotype-phenotype correlations have been done. Moreover, as for any other thrombotic disorder, we could expect that additional factors may modulate the risk of thrombosis in AT deficiency, even for carriers of the same genetic defect.

Objective In this study, the investigators will retrospectively and prospectively collect data on all AT deficient patients diagnosed in or referred to our center for diagnostic work up. The data will be used to create a national registry of antithrombin deficient patients.

The data collected in this registry will allow to gain more insight into what drives the development of a thrombotic event in patients with AT deficiency, both at the environmental level (lifestyle, management of risk situations, presence of additional thrombotic risk factors…) and at the genetic level. Data on obstetric complications and use of anticoagulant drugs will also be collected.

The study will help to assess the thromboembolic risk linked to distinct mutations and different (sub)types of AT deficiency. The findings could help steering the therapeutic attitude and give clinicians the opportunity to propose a more individually, patient-based approach for anticoagulation.

Furthermore, the observations will form the basis for more fundamental research into the pathophysiology of thrombosis in antithrombin deficient patients.

The registry will enroll as many confirmed or suspected hereditary AT deficiency patients as possible; there is no cap on enrollment. The registry enrollment and follow-up periods are open-ended. The endpoints for patients with confirmed or suspected hereditary AT deficiency are death or withdrawal of consent.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1000
• Est. completion date: December 2060
• Est. primary completion date: December 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with genetically confirmed antithrombin deficiency

• Patients with phenotypic antithrombin deficiency in which the genetic defect has not been elucidated yet.

Related Conditions & MeSH terms

• Antithrombin III Deficiency

Intervention

Other:
• observation
No interventions planned: treatment of patients at the discretion of the treating/responsible physician

Locations

Country	Name	City	State
Belgium	UZ Brussel	Brussel

Sponsors (1)

Lead Sponsor	Collaborator
Universitair Ziekenhuis Brussel

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in occurrence of thromboembolic events over time	Inquiry on occurrence of thromboembolic event by means of questionnaire	Every 2 years for a period of 25 years or until death, whichever comes first
Primary	Change in occurrence of arterial thrombotic events over time	Inquiry on occurrence of arterial thrombotic event by means of questionnaire	Every 2 years for a period of 25 years or until death, whichever comes first
Primary	Change in occurrence of obstetric complications over time	Inquiry on occurrence of obstetric complications by means of questionnaire	Every 2 years for a period of 25 years or until death, whichever comes first
Secondary	Change in disease-modifying factors: thrombotic risk factors	collection of disease-modifying factors by means of questionnaire	Every 2 years for a period of 25 years or until death, whichever comes first
Secondary	Change in anticoagulant treatment	collect data on use of anticoagulant treatment by means of questionnaire	Every 2 years for a period of 25 years or until death, whichever comes first